|Rapid Review complete
|For the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Evaluation Recommended at the submitted price.
The HSE has approved reimbursement following confidential price negotiations.